Skip to main content

Table 2 Cancer incidence among dermatomyositis and polymyositis patients by age, gender and years of follow-up

From: Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan

  Dermatomyositis group (n = 1,012) Polymyositis group (n = 643)
  Observed Expected SIR (95% CI) Observed Expected SIR (95% CI)
Total 95 18.58 5.11 (5.01 to 5.22) 33 15.36 2.15 (2.08 to 2.22)
Age       
   <20 years 1 0.13 7.86 (6.26 to 9.36) 0 0.02 -
   20 to 39 years 8 1.11 7.20 (6.72 to 7.72) 7 0.65 10.69 (9.99 to 11.60)
   40 to 59 years 55 6.67 8.25 (8.03 to 8.47) 13 4.98 2.61 (2.47 to 2.76)
   60 to 79 years 29 5.40 5.37 (5.18 to 5.57) 13 6.80 1.91 (1.81 to 2.02)
   ≥ 80 years 2 0.24 8.47 (7.22 to 9.57) 0 0.52 -
Gender       
   Male 39 7.16 5.44 (5.28 to 5.62) 12 6.51 1.84 (1.74 to 1.95)
   Female 56 10.99 5.10 (4.96 to 5.23) 21 8.89 2.36 (2.26 to 2.47)
Follow-up       
   <1 years 64 3.00 21.30 (20.81 to 21.86) 18 2.67 6.75 (6.43 to 7.06)
   1 to 2 years 12 2.36 5.08 (4.80 to 5.38) 3 2.30 1.31 (1.16 to 1.46)
   2 to 5 years 13 5.16 2.52 (2.38 to 2.66) 5 4.93 1.01 (0.93 to 1.11)
   >5 years 6 4.39 1.37 (1.26 to 1.48) 7 3.51 1.99 (1.85 to 2.15)
  1. Expected cancer cases were calculated by age-specific and gender-specific estimates of the general population in Taiwan 2006. CI, confidence interval; SIR, standardized incidence ratio.